The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.

scientific article published on 10 March 2011

The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/MOL.110.070565
P698PubMed publication ID21393385
P5875ResearchGate publication ID50363756

P2093author name stringZakaria Ezzoukhry
Jean-Claude Mazière
Antoine Galmiche
Catherine François
Zuzana Saidak
Christophe Louandre
Corinne Godin
P433issue6
P304page(s)997-1004
P577publication date2011-03-10
P1433published inMolecular PharmacologyQ1943386
P1476titleThe Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
P478volume79

Reverse relations

cites work (P2860)
Q38025197BCL-2 family of proteins and mammary cellular fate
Q37235693BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Q34611338Behavior of solvent-exposed hydrophobic groove in the anti-apoptotic Bcl-XL protein: clues for its ability to bind diverse BH3 ligands from MD simulations
Q34676382Effect of different culture systems and 3, 5, 3'-triiodothyronine/follicle-stimulating hormone on preantral follicle development in mice.
Q37138390Regulation of tumor necrosis factor-α-induced microvascular endothelial cell hyperpermeability by recombinant B-cell lymphoma-extra large
Q33915473Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches.
Q53056599The evaluation of human tenon's fibroblasts and endothelial cell responses to antifibrotics alone and in combination with α-tocopherol.
Q42117299Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine

Search more.